Stockholm, 2015-11-11 08:30 CET (GLOBE NEWSWIRE) --
The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting that is to be held on April 14, 2016. The Nomination Committee consists of Staffan Persson, Peter Lindell and Astrid Samuelsson. The members of the Nomination Committee have been appointed by PledPharma’s three largest shareholders. The Nomination Committee has elected Staffan Persson as Chairman of the Committee. Håkan Åström (Chairman of PledPharma) has been co-opted to the Nomination Committee.
The Committee's task is to present to the Annual General Meeting proposals regarding Chairman and other members of the board as well as fees and other remuneration to the Board´s members. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2017.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email: hakanastrom@aol.com
For more information please contact:
Håkan Åström, Chairman, phone: +46 703 747 213
Jacques Näsström, CEO, phone: +46 737 130 979
jacques.nasstrom@pledpharma.se
About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a condition that can be caused by chemotherapy treatment and acetaminophen (paracetamol) poisoning. The company's most advanced project PledOx® reduces the nerve damage associated with chemotherapy. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. The project PP-099 seeks to limit the damage that occurs to the heart muscle during myocardial infarction. PledPharma’s most advanced project with PledOx® has completed Phase II trial. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bankaktiebolag is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se
